The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
In her Fall Clinical interview, Murina highlighted several key takeaways related to her talk titled ‘Managing Psoriasis with Oral Therapy: 2024 & Beyond.’
Second-Line Obeticholic Acid for PBC Used Infrequently and with Delays
Data from ACG 2024 show only 1 in 12 patients eligible for second-line PBC therapy are actually doing receiving it—and it may take up to a year to initiate.
Hormone Replacement Therapy Linked to Greater IBS, Gastric Motility Disorder Risk
Jacqueline Khalil, DO, reviews findings from 2 studies about the association between hormone replacement therapy with IBS and gastric motility disorders.
ChatGPT Reliable for Gastrointestinal Disease-Based Diet Advice
ChatGPT may provide helpful information around gastroparesis, IBS and celiac disease diets, according to findings from a new study.
GLP-1 RAs Increase Residual Gastric Content But Pose Low Medical Risk During Endoscopy
Braden Kuo, MD, explains how GLP-1 RA use increases residual gastric content but does not significantly impact negative endoscopy outcomes.
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
This interview from Fall Clinical covers 2 additional tips for clinical practice as well as unmet needs among patients.
Abdul Abdellatif, MD: Early Osteopenia Interventions Needed for Patients With Kidney Disease and Gout
Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.
Brian Lacy, MD, PhD: Profiling Gastric Activity Variations with Multiday Testing
Lacy explains the potential value of an ambulatory wireless patch test for identifying unique gastric activity patterns and individualizing patient care.
Christine N. Kay, MD: TEASE Trials Show Promise of Gildeuretinol for Stargardt
At AAO 2024, Kay presented an overview of gildeuretinol, an oral vitamin A derivative offering hope for patients with Stargardt disease.
Ronnie Fass, MD: On-Demand Vonoprazan for Non-Erosive GERD “Within Our Reach”
Fass reviews findings from a post hoc analysis of a phase 2 trial suggesting the value of vonoprazan as an on-demand NERD treatment.
Discussing Unmet Needs for Skin Cancer with Laura K. Ferris, MD, PhD, and Neal Bhatia, MD
In this interview at Fall Clinical Dermatology, Ferris and Bhatia highlighted several elements of skin cancer detection and management as well as unmet needs of patients.
Carla Nester, MD: 12-Month Data Informs Potential of Iptacopan in C3 Glomerulopathy
Carla Nester, MD, discusses her perspective on the APPEAR-C3G 12-month data from ASN Kidney Week 2024.
12-Month APPEAR-C3G Data Highlight Potential of Iptacopan in C3 Glomerulopathy
The APPEAR-C3G trial’s 12-month data show Novartis’ iptacopan significantly reduced proteinuria in C3G, with sustained renal improvements and stable eGFR.
Basile Njei, MD, MPH, PhD: Increasing Lean MASLD Awareness, Improving Screening
Njei points to the need for improved lean MASLD screening, citing findings from his research about its prevalence and the burden of undiagnosed disease.
2 Helpful Clinical Tips for Dermatologists, with Eingun James Song, MD
This Fall Clinical Dermatology Conference interview with Song features a discussion regarding several useful clinical pearls for dermatologists.
Vitamin D Deficiency Linked to Worse IBD Hospital Outcomes
New ACG 2024 data show patients with both IBD and vitamin D deficiency face longer, more expensive hospital stays, as well as risk of colectomy.
Timothy Ritter, MD: Real-World Data Supporting Fecal Microbiota for Recurrent C Diff
Ritter reviews findings from 2 real-world studies supporting the safety and efficacy of live-jslm (Rebyota) for recurrent C Diff infection.
AIMS65 Could Predict Treated Gastrointestinal Bleed Death, Rebleed Risks
New late-breaking ACG 2024 data supports AIMS65 as a risk factor tool for patients undergoing anticoagulant reversal.
Zegocractin Significantly Improves Acute Pancreatitis Symptoms in Phase 2 CARPO
The CRAC channel inhibitor zegocractin significantly improved acute pancreatitis patients' time to eating food and risk of respiratory failure in new data.
Infliximab Improves Ulcerative Colitis, Crohn's Disease Regardless of Immunosuppressants
Post hoc analyses from the LIBERTY trials support infliximab as either a monotherapy or combination therapy for ulcerative colitis or Crohn's disease.
Collaboration, Intralesional Therapies for Skin Cancer, with Laura K. Ferris, MD, PhD, and Neal Bhatia, MD
This interview features a discussion with Bhatia and Ferris regarding the necessity of collaboration between dermatologists and oncologists for skin cancer.
What Are Some Other Methods To Manage Skin Cancer Outside of Biopsies?
In this interview, Neal Bhatia, MD, and Laura Korb Ferris, MD, PhD, spoke on their Fall Clinical Conference talk titled ‘Beyond the Biopsy: Other Methods To Help Us Manage Skin Cancer.’
Brian Lacy, MD, PhD: Rethinking Motility Testing with a Noninvasive Wireless Patch System
Lacy explains limitations to current motility measurements and reviews findings from his study exploring the potential of a wireless motility patch system.
Kidney Compass: Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024
Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
This interview with Bunick highlighted the Level Up phase 3b/4 trial findings regarding upadacitinib treatment of patients with atopic dermatitis.
Kidney Compass: Atacicept for IgAN with Jonathan Barratt, MD, PhD, at Kidney Week 2024
Neuen, Wadhwani, and Barratt discuss atacicept promise in IgA nephropathy based on phase 2b ORIGIN OLE results, at-home use, and the future of kidney disease care.
ORIGIN OLE Data Solidify Atacicept Disease-Modifying Potential for IgA Nephropathy
New ORIGIN trial data show atacicept may slow kidney decline in IgA nephropathy to rates seen with healthy aging, with notable reductions in Gd-IgA1 and UPCR.
Julie Refardt, MD, PhD: Current Hyponatremia Clinical Interventions Sufficient
Refardt discussed findings from the largest hyponatremia trial ever conducted, including 2174 participants across 9 European centers.
Patient-Reported Outcomes for Roflumilast Foam Highlighted for Seborrheic Dermatitis
These findings from the phase 3 STRATUM trial suggest significant DLQI score improvements as early as the second week of treatment with roflumilast foam.
Dapagliflozin Lowers Risk of Decline in Late-Stage Kidney Disease
The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.